Deficiency of Multidrug Resistance 2 Contributes to Cell Transformation Through Oxidative Stress

Overview

Journal Carcinogenesis

Specialty Oncology

Date 2015 Nov 7

PMID 26542370

Citations 5

Authors

Ali Tebbi

Florence Levillayer

Gregory Jouvion

Laurence Fiette

Guillaume Soubigou

Hugo Varet

Nesrine Boudjadja

Stefano Cairo

Kosuke Hashimoto

Ana Maria Suzuki

Piero Carninci

Annamaria Carissimo

Diego di Bernardo

Yu Wei

Affiliations

Soon will be listed here.

Abstract

Multidrug resistance 2 (Mdr2), also called adenosine triphosphate-binding cassette B4 (ABCB4), is the transporter of phosphatidylcholine (PC) at the canalicular membrane of mouse hepatocytes, which plays an essential role for bile formation. Mutations in human homologue MDR3 are associated with several liver diseases. Knockout of Mdr2 results in hepatic inflammation, liver fibrosis and hepatocellular carcinoma (HCC). Whereas the pathogenesis in Mdr2 (-/-) mice has been largely attributed to the toxicity of bile acids due to the absence of PC in the bile, the question of whether Mdr2 deficiency per se perturbs biological functions in the cell has been poorly addressed. As Mdr2 is expressed in many cell types, we used mouse embryonic fibroblasts (MEF) derived from Mdr2 (-/-) embryos to show that deficiency of Mdr2 increases reactive oxygen species accumulation, lipid peroxidation and DNA damage. We found that Mdr2 (-/-) MEFs undergo spontaneous transformation and that Mdr2 (-/-) mice are more susceptible to chemical carcinogen-induced intestinal tumorigenesis. Microarray analysis in Mdr2-/- MEFs and cap analysis of gene expression in Mdr2 (-/-) HCCs revealed extensively deregulated genes involved in oxidation reduction, fatty acid metabolism and lipid biosynthesis. Our findings imply a close link between Mdr2 (-/-) -associated tumorigenesis and perturbation of these biological processes and suggest potential extrahepatic functions of Mdr2/MDR3.

Citing Articles

Rodent models of cholestatic liver disease: A practical guide for translational research.

Gijbels E, Pieters A, De Muynck K, Vinken M, Devisscher L Liver Int. 2021; 41(4):656-682.

PMID: 33486884 PMC: 8048655. DOI: 10.1111/liv.14800.

Animal Models of Autoimmune Liver Diseases: a Comprehensive Review.

Liu S, Bian Z, Zhao Z, Wang J, Zhang W, Leung P Clin Rev Allergy Immunol. 2020; 58(2):252-271.

PMID: 32076943 DOI: 10.1007/s12016-020-08778-6.

Cholestatic liver disease results increased production of reactive aldehydes and an atypical periportal hepatic antioxidant response.

Shearn C, Fennimore B, Orlicky D, Gao Y, Saba L, Battista K Free Radic Biol Med. 2019; 143:101-114.

PMID: 31377417 PMC: 6848778. DOI: 10.1016/j.freeradbiomed.2019.07.036.

A novel pathogenic variant of ATP-binding cassette subfamily B member 4 causing gallstones in a young adult.

Ishizawa T, Makino N, Kakizaki Y, Ando Y, Matsuda A, Kobayashi T Clin J Gastroenterol. 2019; 12(6):637-641.

PMID: 31115781 DOI: 10.1007/s12328-019-00991-x.

Early heme oxygenase 1 induction delays tumour initiation and enhances DNA damage repair in liver macrophages of Mdr2 mice.

Barikbin R, Berkhout L, Bolik J, Schmidt-Arras D, Ernst T, Ittrich H Sci Rep. 2018; 8(1):16238.

PMID: 30389969 PMC: 6214975. DOI: 10.1038/s41598-018-33233-0.

References

Chin J, Soffir R, Noonan K, Choi K, Roninson I . Structure and expression of the human MDR (P-glycoprotein) gene family. Mol Cell Biol. 1989; 9(9):3808-20. PMC: 362442. DOI: 10.1128/mcb.9.9.3808-3820.1989. View

Chakravarthy M, Lodhi I, Yin L, Malapaka R, Xu H, Turk J . Identification of a physiologically relevant endogenous ligand for PPARalpha in liver. Cell. 2009; 138(3):476-88. PMC: 2725194. DOI: 10.1016/j.cell.2009.05.036. View

Spiegel S, Foster D, Kolesnick R . Signal transduction through lipid second messengers. Curr Opin Cell Biol. 1996; 8(2):159-67. DOI: 10.1016/s0955-0674(96)80061-5. View

Lee Y, Moore D . Liver receptor homolog-1, an emerging metabolic modulator. Front Biosci. 2008; 13:5950-8. DOI: 10.2741/3128. View

Jacquemin E, de Vree J, Cresteil D, Sokal E, Sturm E, Dumont M . The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood. Gastroenterology. 2001; 120(6):1448-58. DOI: 10.1053/gast.2001.23984. View

Dahan J, Nouet Y, Jouvion G, Levillayer F, Adib-Conquy M, Cassard-Doulcier A . LIM-only protein FHL2 activates NF-κB signaling in the control of liver regeneration and hepatocarcinogenesis. Mol Cell Biol. 2013; 33(16):3299-308. PMC: 3753919. DOI: 10.1128/MCB.00105-13. View

Labalette C, Nouet Y, Levillayer F, Colnot S, Chen J, Claude V . Deficiency of the LIM-only protein FHL2 reduces intestinal tumorigenesis in Apc mutant mice. PLoS One. 2010; 5(4):e10371. PMC: 2860980. DOI: 10.1371/journal.pone.0010371. View

Takahashi H, Lassmann T, Murata M, Carninci P . 5' end-centered expression profiling using cap-analysis gene expression and next-generation sequencing. Nat Protoc. 2012; 7(3):542-61. PMC: 4094379. DOI: 10.1038/nprot.2012.005. View

Barash H, R Gross E, Edrei Y, Ella E, Israel A, Cohen I . Accelerated carcinogenesis following liver regeneration is associated with chronic inflammation-induced double-strand DNA breaks. Proc Natl Acad Sci U S A. 2010; 107(5):2207-12. PMC: 2836653. DOI: 10.1073/pnas.0908867107. View

10.

Hochrath K, Krawczyk M, Goebel R, Langhirt M, Rathkolb B, Micklich K . The hepatic phosphatidylcholine transporter ABCB4 as modulator of glucose homeostasis. FASEB J. 2012; 26(12):5081-91. DOI: 10.1096/fj.12-209379. View

11.

Moustafa T, Fickert P, Magnes C, Guelly C, Thueringer A, Frank S . Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury. Gastroenterology. 2011; 142(1):140-151.e12. DOI: 10.1053/j.gastro.2011.09.051. View

12.

Morita S, Kobayashi A, Takanezawa Y, Kioka N, Handa T, Arai H . Bile salt-dependent efflux of cellular phospholipids mediated by ATP binding cassette protein B4. Hepatology. 2007; 46(1):188-99. DOI: 10.1002/hep.21591. View

13.

Tebbi A, Guittet O, Cottet M, Vesin M, Lepoivre M . TAp73 induction by nitric oxide: regulation by checkpoint kinase 1 (CHK1) and protection against apoptosis. J Biol Chem. 2011; 286(10):7873-7884. PMC: 3048674. DOI: 10.1074/jbc.M110.184879. View

14.

Benod C, Vinogradova M, Jouravel N, Kim G, Fletterick R, Sablin E . Nuclear receptor liver receptor homologue 1 (LRH-1) regulates pancreatic cancer cell growth and proliferation. Proc Natl Acad Sci U S A. 2011; 108(41):16927-31. PMC: 3193228. DOI: 10.1073/pnas.1112047108. View

15.

Lee J, Lee Y, Mamrosh J, Busby S, Griffin P, Pathak M . A nuclear-receptor-dependent phosphatidylcholine pathway with antidiabetic effects. Nature. 2011; 474(7352):506-10. PMC: 3150801. DOI: 10.1038/nature10111. View

16.

Tachibana K, Yamasaki D, Ishimoto K, Doi T . The Role of PPARs in Cancer. PPAR Res. 2008; 2008:102737. PMC: 2435221. DOI: 10.1155/2008/102737. View

17.

Katzenellenbogen M, Pappo O, Barash H, Klopstock N, Mizrahi L, Olam D . Multiple adaptive mechanisms to chronic liver disease revealed at early stages of liver carcinogenesis in the Mdr2-knockout mice. Cancer Res. 2006; 66(8):4001-10. DOI: 10.1158/0008-5472.CAN-05-2937. View

18.

Greten F, Eckmann L, Greten T, Park J, Li Z, Egan L . IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 2004; 118(3):285-96. DOI: 10.1016/j.cell.2004.07.013. View

19.

Potikha T, Stoyanov E, Pappo O, Frolov A, Mizrahi L, Olam D . Interstrain differences in chronic hepatitis and tumor development in a murine model of inflammation-mediated hepatocarcinogenesis. Hepatology. 2013; 58(1):192-204. DOI: 10.1002/hep.26335. View

20.

van Til N, Heutinck K, van der Rijt R, Paulusma C, van Wijland M, Markusic D . Alteration of viral lipid composition by expression of the phospholipid floppase ABCB4 reduces HIV vector infectivity. Retrovirology. 2008; 5:14. PMC: 2265746. DOI: 10.1186/1742-4690-5-14. View